<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682691</url>
  </required_header>
  <id_info>
    <org_study_id>MS-381-2020</org_study_id>
    <nct_id>NCT04682691</nct_id>
  </id_info>
  <brief_title>Effect on Gastric Residual Volume</brief_title>
  <official_title>Comparison of the Effect of Metoclopramide Versus Erythromycin on Gastric Residual Volume</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In emergencies, it may be necessary to anaesthetize who are not fully starved and&#xD;
      consequently at risk of pulmonary aspiration. Pregnancy are recognized to be at increased&#xD;
      risk of aspiration compared with non-pregnancy. Prokinetic agents such as metoclopramide can&#xD;
      be used to reduce GRV. Metoclopramide is widely used as a prokinetic agent in adults and is&#xD;
      licensed for premedication in pregnancy, but its use may be limited by its potential for&#xD;
      producing extrapyramidal side effects. Erythromycin is an effective prokinetic agent in&#xD;
      adults but there is no work examining its use for premedication in pregnancy. This study&#xD;
      compared the effects of erythromycin and metoclopramide on GRV in full-term pregnant women&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Gastric volume</measure>
    <time_frame>UP TO 24 HOURE</time_frame>
    <description>(mL) based on the antral CSA in the RLD (CSARLD) by gastric ultrasonic after administration of the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration for performing the ultrasound scanning</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>minute</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Gastric Residual Volume</condition>
  <arm_group>
    <arm_group_label>Group (C)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>who will receive flavored water in total volume 15 ml at two hours preoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (M)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will be receive 10 ml of oral metoclopramide (10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (E)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive 10 ml of oral Erythromycin (400mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin (400mg)</intervention_name>
    <description>parturients will receive oral Erythromycin (400mg)</description>
    <arm_group_label>Group (E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide (10mg)</intervention_name>
    <description>will be receive oral metoclopramide (10mg)</description>
    <arm_group_label>Group (M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>naturally flavored water</intervention_name>
    <description>will be receive naturally flavored water</description>
    <arm_group_label>Group (C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-laboring pregnant women â‰¥36 weeks gestational age&#xD;
&#xD;
          -  Parturient scheduled for elective caesarian delivery.&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Having followed institutional fasting guidelines (a minimum of 2 h for clear fluids, 6&#xD;
             h for a light meal, and 8 h for a meal that included fried or fatty food)&#xD;
&#xD;
             2. Exclusion criteria:&#xD;
&#xD;
          -  Refusal of the patient&#xD;
&#xD;
          -  Deviation from fasting times&#xD;
&#xD;
          -  Patients with empty stomach&#xD;
&#xD;
          -  Emergency operation&#xD;
&#xD;
          -  Body mass index (BMI) greater than 40 kg/m2&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status class III, IV.&#xD;
&#xD;
          -  Gestational diabetes mellitus&#xD;
&#xD;
          -  Multiple gestations&#xD;
&#xD;
          -  Patients with polyhydramnios liquor.&#xD;
&#xD;
          -  Preeclampsia patients&#xD;
&#xD;
          -  Chronic kidney disease patients&#xD;
&#xD;
          -  Systemic diseases may cause delayed gastric emptying (eg: myopathies and myasthenia&#xD;
             gravis).&#xD;
&#xD;
          -  Patients with gastrointestinal diseases such as hiatus hernia, intestinal disease and&#xD;
             gastro-oesophageal reflux disease and patients with history of upper gastrointestinal&#xD;
             surgeries.&#xD;
&#xD;
          -  Patients on antidepressants and monoamine oxidase inhibitors&#xD;
&#xD;
          -  Use of other medications known to affect gastric motility or secretions.&#xD;
&#xD;
          -  Allergy to macrolide or metoclopramide&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Cairo University.</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Samir Wahdan</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, Pain management and Surgical ICU</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

